• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Prenetics Announces Third Quarter 2024 Financial Results

    11/27/24 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email

    Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially

    Officially Launched IM8Health.com, a new premium supplements brand

    Tencent Invests $30 million in Insighta's Early Cancer Detection

    Reiterates Revenue Target to Exceed $33 million for FY 2024

    CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the third quarter ended September 30, 2024, along with recent business updates.

    Third Quarter 2024 Financial Highlights

    • Revenue from continuing operations of $7.8 million, as compared to $4.9 million in the third quarter 2023, an increase of 59.4%.
    • Gross profit from continuing operations of $3.9 million, as compared to $1.7 million in the third quarter of 2023, an increase of 138.6%.
    • Gross margin of continuing operations increased to 50.8% from 33.9% in the third quarter 2023, driven by operational efficiencies, better pricing strategies, and cost optimization measures.
    • Adjusted EBITDA1 loss from continuing operations of $5.8 million, an improvement compared to $6.1 million in the third quarter 2023.
    • Cash and other short-term assets2 of $69.1 million and debt-free as of September 30, 2024.
    • Insighta3, our early cancer detection venture with Professor Dennis Lo, had a cash balance of $81.6 million on its balance sheet and debt-free as of September 30, 2024.

    Third Quarter 2024 and Subsequent Operational Updates

    • Successfully launched IM8health.com on November 18, 2024 and shipping to 31 countries and regions. Initial customer response has been very positive.
    • Completed the acquisition of Europa Sports Partners: Established Prenetics' U.S. headquarters in Charlotte, NC. Europa, along with its third-party logistics arm Hubmatrix, supported IM8's U.S. launch while undergoing a digital transformation focused on advanced consumer technologies and digital strategies.
    • Consummated Tencent's $30 million strategic investment in Insighta: Collaboration with Tencent leverages their AI resources and healthcare expertise to advance early cancer detection through venture business Insighta.
    • Cash and short-term assets increased to approximately $98 million: Tencent's $30 million secondary investment, boosted cash and other short-term assets.
    • CircleDNA and ACT Genomics are on track to achieve business-unit breakeven by the second half of 2024.

    ___________________

    1 Adjusted EBITDA is defined as loss from operations excluding (1) employee equity-settled share-based payment expenses, (2) depreciation and amortization, (3) amortization of deferred expenses, (4) acquisition and transaction-related costs, (5) strategic realignment and discontinued products impact, and (6) finance income and exchange gain or loss, net. These adjustments are made for items that may not be indicative of our business performance, including non-cash and/or non-recurring items.

    2 Represents current assets, including cash and cash equivalents totaling $31.9 million, financial assets at fair value through profit or loss of $10.9 million, and trade receivables of $5.7 million, amongst other accounting line items under current assets as of September 30, 2024.

    3 As of September 30, 2024, we owned 50% shareholding in Insighta, which was accounted for under equity-accounted investee. Equity-accounted investees, totaling $97.6 million as of September 30, 2024, were classified as non-current assets on our balance sheet.



    Management Commentary


    Danny Yeung, Chief Executive Officer and Co-Founder, remarked: "I am incredibly proud of our team's execution and the strides we've made in launching IM8 Health, a brand that fills a significant unmet need in the health and wellness market with science-backed premium supplements supported by clinical trials and third-party testing. This launch represents a pivotal moment in our growth strategy, reflecting our commitment to innovation and consumer trust. These efforts have also been supported by a strong third quarter, with 59.4% year-over-year revenue growth and 30.9% growth from the second quarter. Improved gross margins further highlight our focus on operational excellence and cost optimization, even as we invest in structuring the Company for IM8's success—including the strategic acquisition of Europa to support our US expansion."

    Mr. Yeung continued, "With Tencent's $30 million investment to purchase secondary shares, Insighta's valuation of $200 million has been validated, further strengthening our financial position. This strategic collaboration will enhance our early cancer detection and diagnostic capabilities by leveraging AI and positions us for future growth. As we approach the close of 2024, we are energized by the growth opportunities arising from our strategic pivot to the US market and are confident in surpassing our FY 2024 revenue target of $33 million. IM8 is not just another launch—it's the start of a transformative journey in consumer health, built on science, innovation, and trust, and we remain committed to driving additional value for our shareholders."

    About Prenetics

    Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand and Europa, one of the largest sports distribution companies in the USA. Our clinical division is led by Insighta, our $200 million venture focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for comprehensive genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer comprehensive DNA tests. Each of Prenetics' units synergistically enhances our global impact on health, embodying our commitment to ‘enhancing life through science'. To learn more about Prenetics, please visit prenetics.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

    Investor Relations Contact:

    [email protected]

    [email protected]

    Angela Cheung

    Investor Relations / Corporate Finance

    Prenetics Global Limited

    [email protected]

    Basis of Presentation

    Non-IFRS Financial Measure has been provided in the financial statements tables included at the end of this press release. An explanation of this measure is also included below under the heading "Non-IFRS Financial Measure".

    Non-IFRS Financial Measure

    To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measure, adjusted EBITDA loss from continuing operations. This non-IFRS financial measure is not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes this non-IFRS financial measure is useful to investors in evaluating the Company's ongoing operating results and trends.

    Management is excluding from some or all of its non-IFRS results (1) Employee equity-settled share-based payment expenses, (2) depreciation and amortization, (3) Amortization of deferred expenses, (4) Acquisition and transaction-related costs, (5) Strategic realignment and discontinued products impact, and (6) finance income and exchange gain or loss, net — items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

    In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA loss from continuing operations (Non-IFRS)" set forth at the end of this document.

     
    PRENETICS GLOBAL LIMITED

    Unaudited consolidated statements of financial position

    (Expressed in United States dollars unless otherwise indicated)
     
     September 30, June 30, December 31,
      2024  2024  2023
    Assets     
    Property, plant and equipment$9,238,067 $4,745,228 $5,777,794
    Intangible assets 11,987,708  12,455,997  13,424,648
    Goodwill 37,363,809  29,170,123  29,170,123
    Interests in equity-accounted investees 97,575,853  97,875,233  98,464,875
    Financial assets at fair value through profit or loss 9,371,064  9,371,064  9,371,064
    Deferred tax assets —  27,627  27,680
    Deferred expenses —  —  3,530,756
    Other non-current assets 1,110,390  968,525  743,173
    Non-current assets 166,646,891  154,613,797  160,510,113
    Deferred expenses 5,648,473  7,710,439  8,312,890
    Inventories 8,932,408  2,878,258  3,126,776
    Trade receivables 5,706,585  4,086,030  4,058,007
    Deposits, prepayments and other receivables 5,857,371  11,797,508  5,284,848
    Amount due from a related company 2,574  2,561  5,123
    Amount due from an equity-accounted investee 139,909  120,966  132,114
    Financial assets at fair value through profit or loss 10,893,094  10,893,094  11,034,200
    Short-term deposits —  —  16,000,000
    Cash and cash equivalents 31,939,164  41,204,165  45,706,448
    Current assets 69,119,578  78,693,021  93,660,406
    Total assets$235,766,469 $233,306,818 $254,170,519
    Liabilities     
    Deferred tax liabilities$2,162,250 $2,238,336 $2,614,823
    Warrant liabilities 205,942  311,152  223,850
    Lease liabilities 3,637,751  1,181,457  867,215
    Other non-current liabilities 346,955  286,047  823,345
    Non-current liabilities 6,352,898  4,016,992  4,529,233
    Trade payables 8,740,592  1,693,564  1,671,019
    Accrued expenses and other current liabilities 8,174,008  6,821,131  8,174,815
    Contract liabilities 5,709,876  5,480,399  6,111,017
    Lease liabilities 2,849,971  1,183,046  1,502,173
    Liabilities for puttable financial instrument4 16,409,452  15,707,143  14,622,529
    Tax payable 7,433,612  7,402,553  7,402,461
    Current liabilities 49,317,511  38,287,836  39,484,014
    Total liabilities 55,670,409  42,304,828  44,013,247
    Equity     
    Share capital 19,094  19,024  18,308
    Reserves 178,659,723  188,225,181  206,339,490
    Total equity attributable to equity shareholders of the Company 178,678,817  188,244,205  206,357,798
    Non-controlling interests 1,417,243  2,757,785  3,799,474
    Total equity 180,096,060  191,001,990  210,157,272
    Total equity and liabilities$235,766,469 $233,306,818 $254,170,519



     
    PRENETICS GLOBAL LIMITED

    Unaudited consolidated statements of profit or loss and other comprehensive income

    (Expressed in United States dollars unless otherwise indicated)
     
     Nine Months Ended
     September 30,

      September 30,

     
      2024   2023 
       (Restated)

     
    Continuing operations   
    Revenue$20,132,902  $16,314,215 
    Direct costs (8,634,517)  (10,154,500)
    Gross profit 11,498,385   6,159,715 
    Other income and other net gain 1,451,384   3,791,541 
    Selling and distribution expenses5 (6,230,284)  (6,334,964)
    Research and development expenses5 (8,344,625)  (9,830,791)
    Administrative and other operating expenses5 (29,951,055)  (32,420,130)
    Loss from operations (31,576,195)  (38,634,629)
    Fair value loss on financial assets at fair value through profit or loss (141,106)  (3,944,407)
    Fair value gain on warrant liabilities 17,908   2,679,485 
    Share of loss of equity-accounted investees (909,455)  (170,717)
    Other finance costs (124,370)  (120,735)
    Loss before taxation (32,733,218)  (40,191,003)
    Income tax credit 450,479   164,199 
    Loss from continuing operations (32,282,739)  (40,026,804)
    Discontinued operation   
    Profit/(loss) from discontinued operation, net of tax6 18,582   (7,234,839)
    Loss for the period (32,264,157)  (47,261,643)
    Other comprehensive income for the period   
    Item that may be reclassified subsequently to profit or loss:   
    Exchange difference on translation of foreign operations (296,142)  677,474 
    Total comprehensive income for the period$(32,560,299) $(46,584,169)
    Loss attributable to:   
    Equity shareholders of Prenetics$(29,962,285) $(45,776,458)
    Non-controlling interests (2,301,872)  (1,485,185)
     $(32,264,157) $(47,261,643)
    Total comprehensive income attributable to:   
    Equity shareholders of Prenetics$(30,178,068) $(44,534,436)
    Non-controlling interests (2,382,231)  (2,049,733)
     $(32,560,299) $(46,584,169)
    Loss per share:   
    Basic (2.42)  (4.18)
    Diluted (2.42)  (4.18)
    Loss per share - Continuing operations:   
    Basic (2.42)  (3.52)
    Diluted (2.42)  (3.52)
    Weighted average number of common shares:   
    Basic 12,388,243   10,964,344 
    Diluted 12,388,243   10,964,344 



     
    PRENETICS GLOBAL LIMITED

    Unaudited consolidated statements of profit or loss and other comprehensive income

    (Expressed in United States dollars unless otherwise indicated)
     
     Three Months Ended
     September 30,

      June 30,

      September 30,

     
      2024   2024   2023 
             (Restated)

     
    Continuing operations     
    Revenue$7,777,973  $5,941,532  $4,878,941 
    Direct costs (3,830,506)  (2,173,260)  (3,224,316)
    Gross profit 3,947,467   3,768,272   1,654,625 
    Other income and other net (loss)/gain (48,625)  752,118   1,627,592 
    Selling and distribution expenses5 (1,915,373)  (2,416,438)  (1,662,029)
    Research and development expenses5 (2,588,117)  (3,025,458)  (4,004,476)
    Administrative and other operating expenses5 (11,203,672)  (9,687,454)  (10,559,225)
    Loss from operations (11,808,320)  (10,608,960)  (12,943,513)
    Fair value loss on financial assets at fair value through profit or loss —   (141,106)  — 
    Fair value gain/(loss) on warrant liabilities 105,210   (167,888)  926,739 
    Share of (loss)/profit of equity-accounted investees (329,512)  (363,698)  54,567 
    Other finance costs (80,552)  (27,479)  (35,492)
    Loss before taxation (12,113,174)  (11,309,131)  (11,997,699)
    Income tax credit 75,307   89,234   11,544 
    Loss from continuing operations (12,037,867)  (11,219,897)  (11,986,155)
    Discontinued operation     
    (Loss)/profit from discontinued operation, net of tax6 (28,963)  74,160   (2,094,298)
    Loss for the period (12,066,830)  (11,145,737)  (14,080,453)
    Other comprehensive income for the period     
    Item that may be reclassified subsequently to profit or loss:     
    Exchange difference on translation of foreign operations 474,278   (339,976)  (480,209)
    Total comprehensive income for the period$(11,592,552) $(11,485,713) $(14,560,662)
    Loss attributable to:     
    Equity shareholders of Prenetics$(10,672,236) $(10,721,954) $(13,570,455)
    Non-controlling interests (1,394,594)  (423,783)  (509,998)
     $(12,066,830) $(11,145,737) $(14,080,453)
    Total comprehensive income attributable to:     
    Equity shareholders of Prenetics$(10,252,010) $(10,924,679) $(14,000,699)
    Non-controlling interests (1,340,542)  (561,034)  (559,963)
     $(11,592,552) $(11,485,713) $(14,560,662)
    Loss per share:     
    Basic$(0.84) $(0.88) $(1.16)
    Diluted (0.84)  (0.88)  (1.16)
    Loss per share - Continuing operations:     
    Basic (0.84)  (0.88)  (0.98)
    Diluted (0.84)  (0.88)  (0.98)
    Weighted average number of common shares:     
    Basic 12,722,810   12,222,337   11,743,434 
    Diluted 12,722,810   12,222,337   11,743,434 



     
    PRENETICS GLOBAL LIMITED

    Non-IFRS Financial Measures

    (Expressed in United States dollars unless otherwise indicated)
     
    Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA loss from continuing operations (Non-IFRS)
     
     Nine Months Ended
     September 30,

      September 30,

     
      2024   2023 
         (Restated)

     
    Loss from operations from continuing operations under IFRS$(31,576,195) $(38,634,629)
    Employee equity-settled share-based payment expenses 4,861,707   10,632,798 
    Depreciation and amortization 4,530,392   5,106,206 
    Amortization of deferred expenses 6,195,173   6,064,443 
    Acquisition and transaction-related costs 1,824,210   — 
    Strategic realignment and discontinued products impact 162,678   1,767,296 
    Finance income, exchange gain or loss, net (1,362,803)  (3,579,732)
    Adjusted EBITDA loss from continuing operations (Non-IFRS)$(15,364,838) $(18,643,618)



     Three Months Ended
     September 30,

      June 30,

      September 30,

     
      2024   2024   2023 
             (Restated)

     
    Loss from operations from continuing operations under IFRS$(11,808,320) $(10,608,960) $(12,943,513)
    Employee equity-settled share-based payment expenses 1,388,861   1,535,578   4,348,329 
    Depreciation and amortization 1,377,068   1,433,769   1,703,843 
    Amortization of deferred expenses 2,061,966   2,044,934   2,062,142 
    Acquisition and transaction-related costs 1,025,900   798,310   — 
    Strategic realignment and discontinued products impact 125,394   28,994   345,578 
    Finance income, exchange gain or loss, net 31,980   (694,194)  (1,634,998)
    Adjusted EBITDA loss from continuing operations (Non-IFRS)$(5,797,151) $(5,461,569) $(6,118,619)

    ___________________

    4 In connection with the acquisition of ACT Genomics, the remaining shareholders of ACT Genomics - representing 25.61% of the fully diluted shareholding of ACT Genomics that Prenetics does not own - were granted put options which allow these remaining shareholders to put their remaining shares to Prenetics under certain conditions. The liabilities arising from such put option are recorded as liabilities for puttable financial instrument, and are valued at the present value of the exercise price of the put option. As of September 30, 2024, the shareholding of ACT Genomics was diluted, with the remaining shareholders holding 26.73%.

    5 Includes equity-settled share-based payment expenses from continuing operations as follows:

     Nine Months Ended
     September 30, September 30,
      2024  2023
       (Restated)
    Direct costs$1,026 $—
    Selling and distribution expenses 5,054  100,561
    Research and development expenses 2,258,374  2,891,754
    Administrative and other operating expenses 2,360,340  7,576,866
    Total equity-settled share-based payment expenses$4,624,794 $10,569,181



     Three Months Ended
     September 30,

     June 30,

     September 30,

     
      2024  2024  2023 
           (Restated)

     
    Direct costs$5 $440 $— 
    Selling and distribution expenses 3,591  410  (3,307)
    Research and development expenses 689,530  810,450  1,530,858 
    Administrative and other operating expenses 504,597  699,991  2,798,696 
    Total equity-settled share-based payment expenses$1,197,723 $1,511,291 $4,326,247 
              

    6 We ceased our COVID-19 testing business entirely in 2023 Q2, and other DNA testing operations in the EMEA regions in 2023 Q4. As a result, COVID-19 testing business and the operations in the EMEA regions are reported as a discontinued operation under IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. In accordance with IFRS 5, the results of the discontinued operation have been presented separately from the continuing operations in the consolidated statements of profit or loss and other comprehensive income.



    Primary Logo

    Get the next $PRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

      Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

      1/18/23 7:56:45 AM ET
      $PRE
      Blank Checks
      Finance
    • Citigroup initiated coverage on Prenetics Group Ltd.

      Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

      7/12/22 11:48:35 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    SEC Filings

    See more
    • SEC Form S-8 filed by Prenetics Global Limited

      S-8 - Prenetics Global Ltd (0001876431) (Filer)

      5/7/25 8:47:19 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 20-F filed by Prenetics Global Limited

      20-F - Prenetics Global Ltd (0001876431) (Filer)

      4/30/25 4:44:18 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 6-K filed by Prenetics Global Limited

      6-K - Prenetics Global Ltd (0001876431) (Filer)

      3/5/25 8:34:06 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded Event

      David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8's Vision for Elite Wellness Accessible to All CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- On Monday, IM8, the premium supplement brand co-founded by David Beckham, hosted IM8 Vibrante - A Celebration of Science, Wellness & Flavor, a memorable evening at the iconic Faena Theater on Miami Beach. In attendance were nearly 150 wellness influencers, creators, science and medical advisors, and media members to celebrate the brand's ongoing commitment to transforming the status quo of wellness by blending innovation in science and medicine while prioritizing holistic he

      4/9/25 9:00:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

      Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) --  IM8, the premium supplements brand co-founded by David Beckham, today announced the addition of two distinguished new members, Dr. Jeremy London and Dr. Amy Shah, to its world-class Scientific Advisory Board (SAB). These additions underscore IM8's unwavering commitment to leading innovation in science, longevity and human performance. Newly joining IM8's SAB are: Dr. Amy Shah – An acclaimed integrative medicine physician and double board-certified expert in Internal Medicine, Dr. Shah focuses on g

      3/18/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics to Participate in the 37th Annual ROTH Conference

      CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Prenetics' Chief Executive Officer Danny Yeung and President of Americas David Vanderveen will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a panel discussion on Longevity and Supplementation on Monday, March 17th at 12:00pm PT. Interested parties may access the panel through the webcast link here w

      3/11/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

      LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

      7/1/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

      (From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

      2/9/24 9:25:22 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Financials

    Live finance-specific insights

    See more
    • Prenetics Announces Third Quarter 2024 Financial Results

      Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the third quarter ended September 30, 2024, along with recent business updates. Third Quarter 2024 Financial Highlights Revenue from continuing operations of $7.8 million, as compared to $4.9 million in the thi

      11/27/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Second Quarter 2024 Financial Results

      Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

      10/7/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry

      Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

      8/19/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/14/24 12:30:15 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      2/5/24 6:05:14 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/27/23 6:05:43 AM ET
      $PRE
      Blank Checks
      Finance